Recombinant protein · Inhibitor of Soluble tumor necrosis factor (TNF-alpha) (TNF) · developed by Inmune Bio
Pegipanermin is a pegylated, engineered dominant-negative TNF-alpha variant lacking TNF receptor-binding activity. It forms heterotrimers with soluble TNF, preventing it from binding TNF receptors and reducing pro-inflammatory signaling. It is being studied in COVID-19 and in Alzheimer disease and related dementias.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04370236 | Phase 2/3 | COVID-19 | Terminated | INMB |
| NCT05318976 | Phase 2 | Alzheimer Disease | Completed | INMB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer DiseaseBrain DiseasesCentral Nervous System DiseasesCOVID-19DementiaMental DisordersMild Cognitive ImpairmentNervous System DiseasesNeurocognitive DisordersNeurodegenerative DiseasesTauopathies
Updated Oct 18, 2026. Something wrong or missing? Report it on the INMB page.
See INMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INMB catalysts and pipeline →